The prospect of using affibodies as a tool for diagnostics and cancer treatment is confirmed by a wide range of fundamental research directed toward the design of diagnostic and therapeutic structures [82,83] and ongoing clinical trials of a radioactively labeled anti-HER2 affibody ZHER2:342 for the treatment of human breast cancer [29]. This evidence concerns the gene ERBB2 and cancer.